skip to content
Primary navigation

Ilaris

Drug - Ilaris® (canakinumab) [Novartis Pharmaceuticals]

January 2017

Therapeutic area - Auto-inflammatory diseases

Approval criteria

Patient has one of the following diagnosis:

  • Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS)
  • Tumor Necrosis Factor Receptor Associated Period Syndrome (TRAPS)
  • Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
  • Familial Mediterranean Fever (FMF)
  • Systemic Juvenile Idiopathic Arthritis (SJIA) AND meeting criteria as found in the Immunomodulator PA Criteria

Quantity limit

Patient’s most current body weight must be provided at time of request.

Quantity limits depend on patient’s diagnosis.

  • Patients with CAPS and has:
    • Body weight 15 kg to 40 kg: 3 mg/kg every 8 weeks
    • Body weight greater than 40 kg: 150 mg every 8 weeks
  • Patients with TRAPS, HIDS/MKD, FMF and has:
    • Body weight 40 kg or less: 4mg/kg every 4 weeks
    • Body weight greater than 40 kg: 300 mg every 4 weeks

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top